Literature DB >> 2529544

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

W S Griffin1, L C Stanley, C Ling, L White, V MacLeod, L J Perrot, C L White, C Araoz.   

Abstract

Interleukin 1, an immune response-generated cytokine that stimulates astrocyte proliferation and reactivity (astrogliosis), was present in up to 30 times as many glial cells in tissue sections of brain from patients with Down syndrome and Alzheimer disease compared with age-matched control subjects. Most interleukin 1-immunoreactive glia in Down syndrome and Alzheimer disease were classified as microglia. The number of interleukin 1 immunoreactive neurons did not appear to differ in Down syndrome and Alzheimer disease compared with control brain. Numerous temporal lobe astrocytes in Alzheimer disease and postnatal Down syndrome were intensely interleukin 1-, S-100-, and glial fibrillary acidic protein-immunoreactive and had reactive structure. Interleukin 1 levels in Alzheimer disease temporal lobe homogenates were elevated, as were the levels of S-100 and glial fibrillary acidic protein, two proteins reportedly elevated in reactive astrocytes. These data suggest that increased expression of S-100 in Down syndrome, resulting from duplication of the gene on chromosome 21 that encodes the beta subunit of S-100, may be augmented by elevation of interleukin 1. As a corollary, the astrogliosis in Alzheimer disease may be promoted by elevation of interleukin 1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529544      PMCID: PMC298116          DOI: 10.1073/pnas.86.19.7611

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Immunohistochemical co-localization of S-100b and the glial fibrillary acidic protein in rat brain.

Authors:  B E Boyes; S U Kim; V Lee; S C Sung
Journal:  Neuroscience       Date:  1986-03       Impact factor: 3.590

2.  Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression.

Authors:  D H Perlmutter; C A Dinarello; P I Punsal; H R Colten
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

3.  Glial fibrillary acidic protein and S100 protein in abnormal astrocytes in Wilson's disease.

Authors:  M J Mossakowski; H Weinrauder
Journal:  Neuropatol Pol       Date:  1986

4.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

5.  S100ao (alpha alpha) protein is mainly located in the heart and striated muscles.

Authors:  K Kato; S Kimura
Journal:  Biochim Biophys Acta       Date:  1985-10-17

6.  Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2.

Authors:  A C Webb; K L Collins; P E Auron; R L Eddy; H Nakai; M G Byers; L L Haley; W M Henry; T B Shows
Journal:  Lymphokine Res       Date:  1986

7.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease.

Authors:  C R Abraham; D J Selkoe; H Potter
Journal:  Cell       Date:  1988-02-26       Impact factor: 41.582

9.  Glial fibrillary acidic protein and S-100 protein in human hepatic encephalopathy: immunocytochemical demonstration of dissociation of two glia-associated proteins.

Authors:  T Kimura; H Budka
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

10.  Interleukin 1 of the central nervous system is produced by ameboid microglia.

Authors:  D Giulian; T J Baker; L C Shih; L B Lachman
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

View more
  489 in total

1.  S100beta interaction with tau is promoted by zinc and inhibited by hyperphosphorylation in Alzheimer's disease.

Authors:  W H Yu; P E Fraser
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

2.  Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease.

Authors:  L N Nilsson; K R Bales; G DiCarlo; M N Gordon; D Morgan; S M Paul; H Potter
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

Review 3.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

4.  Glial protein S100B modulates long-term neuronal synaptic plasticity.

Authors:  Hiroshi Nishiyama; Thomas Knopfel; Shogo Endo; Shigeyoshi Itohara
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 5.  The pervasiveness of interleukin-1 in alzheimer pathogenesis: a role for specific polymorphisms in disease risk.

Authors:  W S Griffin; J A Nicoll; L M Grimaldi; J G Sheng; R E Mrak
Journal:  Exp Gerontol       Date:  2000-07       Impact factor: 4.032

Review 6.  Local neuroinflammation and the progression of Alzheimer's disease.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

7.  Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo.

Authors:  J G Sheng; S G Zhu; R A Jones; W S Griffin; R E Mrak
Journal:  Exp Neurol       Date:  2000-06       Impact factor: 5.330

8.  Mechanism of interleukin-1- and tumor necrosis factor alpha-dependent regulation of the alpha 1-antichymotrypsin gene in human astrocytes.

Authors:  T Kordula; M Bugno; R E Rydel; J Travis
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

Review 9.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

Review 10.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.